About
Technology
Issues
FAQ
Links
Official Page
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the
F508del-CFTR
mutation
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.